Glucocorticoid-induced osteoporosis and its treatment

Clinical Orthopaedics and Related Research

Volumn 443, Issue , 2006, Pages 39-47

  Pennisi, Pietra ^a   Trombetti, Andrea ^a   Rizzoli, René ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BISPHOSPHONIC ACID DERIVATIVE; BRONCHODILATING AGENT; CALCITONIN; CALCIUM; CLODRONIC ACID; COLECALCIFEROL; COLECALCIFEROL DERIVATIVE; DEXAMETHASONE; ESTROGEN; ETIDRONIC ACID; FLUORIDE; GLUCOCORTICOID; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; PREDNISONE; PROTON PUMP INHIBITOR; RISEDRONIC ACID; SEX HORMONE; VITAMIN D; VITAMIN D DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

APOPTOSIS; ASTHMA; BODY WEIGHT; BONE DENSITY; BONE DISEASE; CALCIUM ABSORPTION; CALCIUM EXCRETION; CANCELLOUS BONE; CONFERENCE PAPER; CORTICAL BONE; EXERCISE; FRACTURE; HIP FRACTURE; HORMONE SYNTHESIS; HUMAN; HYPERCALCIURIA; HYPOGONADISM; MALNUTRITION; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN INTAKE; RISK; URINARY EXCRETION; VERTEBRA FRACTURE; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; KINESIOTHERAPY; METHODOLOGY; REVIEW; TREATMENT OUTCOME;

BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; EXERCISE THERAPY; GLUCOCORTICOIDS; HUMANS; OSTEOPOROSIS; TREATMENT OUTCOME; VITAMIN D;

EID: 33645299091     PISSN: 0009921X     EISSN: 15281132     Source Type: Journal    
DOI: 10.1097/01.blo.0000200238.29931.1f     Document Type: Conference Paper

References (74)

1. Actonel prescribing information (package insert). Procter and Gamble Pharmaceuticals, Cincinnati, Ohio, USA. 2002.
2. Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, Kendler DL, Lentle B, Olszynski W, Ste-Marie LG, Tenenhouse A, Chines AA. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med. 1997;337:382-387.
3. Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, Lane NE, Kaufman JM, Poubelle PE, Hawkins F, Correa-Rotter R, Menkes CJ, Rodriguez-Portales JA, Schnitzer TJ, Block JA, Wing J, McIlwain HH, Westhovens R, Brown J, Melo-Gomes JA, Gruber BL, Yanover MJ, Leite MO, Siminsoki KG, Nevitt MC, Charp JT, Malice MP, Dumortier T, Czachur M, Carofano W, Daifotis A. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: A randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. 2001;44:202-211.
4. Adler RA, Hochberg MC. Suggested guidelines for evaluation and treatment of glucocorticoid-induced osteoporosis for the Department of Veterans Affairs. Arch Intern Med. 2003;163:2619-2624.
5. American College of Rheumatology Ad Hoc Committee on Glucocorticoid- Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum. 2001;44:1496-1503.
6. Amin S, Lavalley MP, Simms RW, Felson DT. The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: A meta-regression. J Bone Miner Res. 2002;17:1512-1526.
7. Arlot ME, Delmas PD, Chappard D, Meunier PJ. Trabecular and endocortical bone remodeling in postmenopausal osteoporosis: Comparison with normal postmenopausal women. Osteoporos Int. 1990;1:41-49.
8. Bonadonna S, Burattin A, Nuzzo M, Bugari G, Bosei EA, Valle D, Iori N, Nilezikian JP, Veldhuis JD, Giustina A. Chronic glucocorticoid treatment alters spontaneous pulsatile parathyroid hormone secretory dynamics in human subjects. Eur J Endocrinol. 2005;152:199-205.
9. Boutsen Y, Jamart J, Esselinckx W, Devogelaer JP. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: A prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. J Bone Miner Res. 2001;16:104-112.
10. Boutsen Y, Jamart J, Esselinckx W, Stoffel M, Devogelaer JP. Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: A randomized trial. Calcif Tissue Int. 1997;61:266-271.
11. Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM. Effects of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis. J Rheumatol. 1997;24:1489-1494.
12. Canalis E. Clinical review 83: Mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis. J Clin Endocrinol Metab. 1996;81:3441-3447.
13. Chappard D, Legrand E, Basle MF, Fromont P, Racineux JL, Rebel A, Audran M. Altered trabecular architecture induced by corticosteroids: A bone histomorphometric study. J Bone Miner Res. 1996;11:676-685.
14. Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M, Zizic TM, Wallach S, Sewell KL, Lukert BP, Axelrod DW, Chines AA. Risedronate therapy prevents corticosteroid-induced bone loss: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 1999;42:2309-2318.
15. Cohen A, Shane E. Osteoporosis after solid organ and bone marrow transplantation. Osteoporos Int. 2003;14:617-630.
16. Cooper C. Osteoporosis in rheumatological practice: Questions to be answered. Ann Rheum Dis. 1995;54:1-2.
17. Cushing H. The basofil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bull Johns Hopkins Hosp. 1932;50:137-195.
18. Danneskiold-Samsoe B, Grimby G. The influence of prednisone on the muscle morphology and muscle enzymes in patients with rheumatoid arthritis. Clin Sci (Lond). 1986;71:693-701.
19. de Nijs RN, Jacobs JW, Algra A, Lems WF, Bijlsma JW. Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: A review with meta-analysis of randomized controlled trials including organ transplantation studies. Osteoporos Int. 2004;15:589-602.
20. Dempster DW, Arlot MA, Meunier PJ. Mean wall thickness and formation periods of trabecular bone packets in corticosteroid-induced osteoporosis. Calcif Tissue Int. 1983;35:410-417.
21. Dequeker J, Westhovens R. Low dose corticosteroid associated osteoporosis in rheumatoid arthritis and its prophylaxis and treatment: Bones of contention. J Rheumatol. 1995;22:1013-1019.
22. Domrongkitchaiporn S, Ongphiphadhanakul B, Stitchantrakul W, Piaseu N, Chansirikam S, Puavilai G, Rajatanavin R. Risk of calcium oxalate nephrolithiasis after calcium or combined calcium and calcitriol supplementation in postmenopausal women. Osteoporos Int. 2000;11:486-492.
23. Eastell R, Reid DM, Compston J, Cooper C, Fogelman I, Francis RM, Hosking DJ, Purdie DW, Ralston SH, Reeve J, Russell RG, Stevenson JC, Torgerson CJ. A UK Consensus Group on management of glucocorticoid-induced osteoporosis: An update. J Intern Med. 1998;244:271-292.
24. Ebeling PR, Erbas B, Hopper JL, Wark JD, Ribinfeld AR. Bone mineral density and bone turnover in asthmatics treated with long-term inhaled or oral glucocorticoids. J Bone Miner Res. 1998;13:1283-1289.
25. Fosamax prescribing information (package insert). Whitehouse Station, NJ: Merck and Co. Inc; 2005.
26. Geusens PP, de Nijs RN, Lems WF, Laan RF, Struijs A, van Staa TP, Bijlsma JW. Prevention of glucocorticoid osteoporosis: a consensus document of the Dutch Society for Rheumatology. Ann Rheum Dis. 2004;63:324-325.
27. Gonnelli S, Rottoli P, Cepollaro C, Pondrelli C, Cappiello V, Vagliasindi M, Gennari C. Prevention of corticosteroid-induced osteoporosis with alendronate in sarcoid patients. Calcif Tissue Int. 1997;61:382-385.
28. Healey JH, Paget SA, Williams-Russo P, Szatrowski TP, Schneider R, Spiera H, Mitnick H, Ales K, Schwartzberg P. A randomized controlled trial of salmon calcitonin to prevent bone loss in corticosteroid-treated temporal arteritis and polymyalgia rheumatica. Calcif Tissue Int. 1996;58:73-80.
29. Hsueh AJ, Erickson GF. Glucocorticoid inhibition of FSH-induced estrogen production in cultured rat granulosa cells. Steroids. 1978;32:639-648.
30. Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med. 2001;345:941-947.
31. Kanis JA. Johansson H, Oden A, et a.: A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res. 2004;19:893-899.
32. Kimberg DV, Baerg RD, Gershon E, Graudusius RT. Effect of cortisone treatment on the active transport of calcium by the small intestine. J Clin Invest. 1971;50:1309-1321.
33. Laan RF, van Riel PL, van de Putte LB, van Erning LJ, van't Hof MA, Lemmens JA. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis: A randomized, controlled study. Ann Intern Med. 1993;119:963-968.
34. Lane NE, Sanchez S, Modin GW, Genant HK, ini E, Arnaud CD. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis: Results of a randomized controlled clinical trial. J Clin Invest. 1998;102:1627-1633.
35. Lau E, Mamdani M, Tu K. Inhaled or systemic corticosteroids and the risk of hospitalization for hip fracture among elderly women. Am J Med. 2003;114:142-145.
36. Lecka-Czernik B, Gubrij I, Moerman EJ, Kajkenova O, Lipschitz DA, Manolagas SC, Jilka RL. Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARgamma2. J Cell Biochem. 1999;74:357-371.
37. Luengo M, del Rio L, Pons F, Picado C. Bone mineral density in asthmatic patients treated with inhaled corticosteroids: A case-control study. Eur Respir J. 1997;10:2110-2113.
38. Luton JP, Thieblot P, Valcke JC, Mahoudeau JA, Bricaire H. Reversible gonadotropin deficiency in male Cushing's disease. J Clin Endocrinol Metab. 1977;45:488-495.
39. MacAdams MR. White RH, Chipps BE. Reduction of serum testosterone levels during chronic glucocorticoid therapy. Ann Intern Med. 1986;104:648-651.
40. Manelli F, Giustina A. Glucocorticoid-induced osteoporosis. Trends Endocrinol Metab. 2000;11:79-85.
41. Manolagas SC. Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev. 2000;21:115-137.
42. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312:1254-1259.
43. McEvoy CE, Ensrud KE, Bender E, Genant HK, Yu W, Griffith JM, Niewoehner DE. Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:704-709.
44. Moreira Kulak CA, Schussheim DH, McMahon DJ, Kurland E, Silverberg SJ, Siris ES, Bilezikian JP, Shane E. Osteoporosis and low bone mass in premenopausal and perimenopausal women. Endocr Pract. 2000;6:296-304.
45. National Institutes of Health Consensus Development Panel on Osteoporosis Prevention Diagnosis and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285:785-795.
46. National Osteoporosis Society & Royal College of Physicians guidelines working group for the Bone and Tooth Society. Glucocorticoid-induced Osteoporosis: Guidelines for the Prevention and Treatment. London, Royal College of Physicians 2002.
47. Ohnaka K, Taniguchi H, Kawate H, Nawata H, Takayanagi R. Glucocorticoid enhances the expression of dickkopf-1 in human osteoblasts: Novel mechanism of glucocorticoid-induced osteoporosis. Biochem Biophys Res Commun. 2004;318:259-264.
48. Pereira RC, Blanquaert F, Canalis E. Cortisol enhances the expression of mac25/insulin-like growth factor-binding protein-related protein-1 in cultured osteoblasts. Endocrinology. 1999;140:228-232.
49. Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest. 1999;104:1363-1374.
50. Reid DM, Hughes RA, Laan RF, Sacco-Gibson NA, Wenderoth DH, Adami S, Eusebio RA, Devogelaer JP. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: A randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res. 2000;15:1006-1013.
51. Reid IR. Glucocorticoid osteoporosis: Mechanisms and management. Eur J Endocrinol. 1997;137:209-217.
52. Reid IR, Wattie DJ, Evans MC, Stapleton JP. Testosterone therapy in glucocorticoid-treated men. Arch Intern Med. 1996;156:1173-1177.
53. Ringe JD, Welzel D. Salmon calcitonin in the therapy of corticoid-induced osteoporosis. Eur J Clin Pharmacol. 1987;33:35-39.
54. Rizzato G, Tosi G, Schiraldi G, Montemurro L, Zanni D, Sisti S. Bone protection with salmon calcitonin (sCT) in the long-term steroid therapy of chronic sarcoidosis. Sarcoidosis. 1988;5:99-103.
55. Rizzoli R, Chevalley T, Slosman DO, Bonjour JP. Sodium monofluorophosphate increases vertebral bone mineral density in patients with corticosteroid-induced osteoporosis. Osteoporos Int. 1995;5:39-46.
56. Rizzoli R, von Tscharner V, Fleisch H. Increase of adenylate cyclase catalytic-unit activity by dexamethasone in rat osteoblast-like cells. Biochem J. 1986;237:447-454.
57. Roux C, Oriente P, Laan R, Hughes RA, Ittner J, Goemaere S, Di Munno O, Pouilles JM, Horlait S, Cortet B. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss: Ciblos Study Group. J Clin Endocrinol Metab. 1998;83:1128-1133.
58. Rubin MR, Bilezikian JP. Clinical review 151. The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: A re-examination of the evidence. J Clin Endocrinol Metab. 2002;87:4033-4041.
59. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis: Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med. 1998;339:292-299.
60. Sakakura M, Takebe K, Nakagawa S. Inhibition of luteinizing hormone secretion induced by synthetic LRH by long-term treatment with glucocorticoids in human subjects. J Clin Endocrinol Metab. 1975;40:774-779.
61. Sambrook P, Birmingham J, Kelly P, Kempler S, Nguyen T, Pocock N, Eisman J. Prevention of corticosteroid osteoporosis: A comparison of calcium, calcitriol, and calcitonin. N Engl J Med. 1993;328:1747-1752.
62. Skrtic S, Ohlsson C. Cortisol decreases hepatocyte growth factor levels in human osteoblast-like cells. Calcif Tissue Int. 2000;66:108-112.
63. Slovik DM, Neer RM, Ohman JL, Lowell FC, Clark MB, Segre GV, Potts JT, Jr. Parathyroid hormone and 25-hydroxyvitamin D levels in glucocorticoid-treated patients. Clin Endocrinol (Oxf). 1980;12:243-248.
64. Spector TD, Sambrook PN. Steroid osteoporosis. BMJ. 1993;307:519-520.
65. Suzuki Y, Ichikawa Y, Saito E, Homma M. Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy. Metabolism. 1983;32:151-156.
66. Trombetti A, Gerbase MW, Spiliopoulos A, Slosman DO, Nicod LP, Rizzoli R. Bone mineral density in lung-transplant recipients before and after graft: Prevention of lumbar spine posttransplantation-accelerated bone loss by pamidronate. J Heart Lung Transplant. 2000;19:736-743.
67. van Staa TP, Bishop N, Leufkens HG, Cooper C. Are inhaled corticosteroids associated with an increased risk of fracture in children? Osteoporos Int. 2004;15:785-791.
68. van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000;15:993-1000.
69. van Staa TP, Leufkens HG, Cooper C. Use of inhaled corticosteroids and risk of fractures. J Bone Miner Res. 2001;16:581-588.
70. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: A meta-analysis. Osteoporos Int. 2002;13:777-787.
71. Wallach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Laan RF, Doherty SM, Maricic M, Rosen C, Brown J, Barton I, Chines AA. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int. 2000;67:277-285.
72. Weinstein RS, Chen JR, Powers CC, Stewart SA, Landes RD, Bellido T, Jilka RL, Parfitt AM, Manolagas SC. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest. 2002;109:1041-1048.
73. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids: Potential mechanisms of their deleterious effects on bone. J Clin Invest. 1998;102:274-282.
74. Wong CA, Walsh LJ, Smith CJ, Wisniewski AF, Lewis SA, Hubbard R, Cawte S, Green DJ, Pringle M, Tattersfield AE. Inhaled corticosteroid use and bone-mineral density in patients with asthma. Lancet. 2000;355:1399-1403.